INTRODUCTION
Atopic dermatitis (AD) (eczema) is a chronically relapsing inflammatory skin disease associated with erythema, scaly and oozing plaques on the forehead and face, neck, hands and flexural areas and severe pruritus (1, 2) . AD affects 2-5% of the general population, with ≥10-20% occurrences in infants and children and 1-3% in adults (3) . There is a wide variation in the prevalence of AD in different populations of the world, and it appears to increasing (4, 5) .
Eczematous skin changes (infantile eczema) of early childhood may differ from common atopic dermatitis in terms of lack of family background of atopy, absence of signs of type I allergies, clinical course, and failure to respond promptly to topical treatment.
Self-healing, the susceptibility to allergy, as well as the characteristic immune profile of lesional skin and peripheral blood are all hallmarks of AD. They together with the 2 different types of AD, the intrinsic and extrinsic types require new definitions and reassessment. According to the recent findings of a search for susceptibility genes, it appears that nonatopic dermatitis should be considered as a distinct entity of childhood eczema. The affected youngsters show dry ichthyosiform and eczematous skin changes at an early age with absence of sensitization to common allergens (6) , and 33% of them should complete clearing within 5 years of age.
The optimal protocol for their management has still not been established (7) . The diagnostic criteria recommended by the American Academy of Dermatology at the 2003 consensus conference are currently used by many clinicians for diagnosis and treatment of children and adults (8) (9) (10) . Moreover, the mechanisms underlying the pathogenesis of AD remain unclear, although numerous studies have demonstrated the integral involvement of immunopathology, genetic predisposition, and emotional and environmental stimuli in AD development and progression (8) . With the intent of bringing uniformity to the diagnosis of AD, Hanifin and Rajka (11) proposed a number of diagnostic criteria based on their clinical 3 3 experience. Williams et al. (12, 13 ) coordinated a UK working party and refined Hanifin and Rajka's criteria for AD, which were suitable for hospital and epidemiological settings. De et al. (14) found statistical advantage in favor of Hanifin and Rajka's criteria (sensitivity 96.4%, specificity 93.75%) compared to the UK working party's diagnostic criteria (sensitivity 86.14%, specificity 95.83%) that reached a level of significant of <0.005. They noted that dermatitis in classical distribution, its chronic relapsing nature, dry skin and infra-orbital folds had relative values and these features were helpful in discriminating cases of AD from controls.
Terminology of AD is controversial, with many different names in different countries, among them neurodermitis, constitutionalis atopica, and atopic eczema. Johansson et al. and the European Academy of Allergology and Clinical Immunology (EAACI) (15) proposed a new term "atopic eczema/dermatitis syndrome" (AEDS) which was divided into non-allergic and allergic types, the latter applying to IgE-associated allergic AEDS. They revised the nomenclature of AD and atopy and called only the IgE-associated forms of the diseases true AD (16) . It is hoped that the term "eczema" will replace the current term AD. Several genetic analyses have identified different chromosome regions with a linkage to AD features: Th2 cell cytokine genes on 5q31-33, on 1q21, 3q21, 17q25 and 20p which are closely with some major psoriasis loci (17, 18) . Further genetic regions associated with AD features include gene polymorphisms, activator of transcription (STAT)-6, the proximal promoter of regulated on activation, normal T-cell expressed and secreted (RANTES), interleukin (IL)-4, IL-4 Rα and transforming growth factor (TGF)-ß (5, 19, 20, 21 ). An association of one region in tron 2 polymorphisms (rs 324011) with total serum IgE and a STAT 6 risk haplotype for elevated IgE in white adults was also proven (21) . Candidate genes found in regions (3q21, 5q31-33 and 11q13) code for various immunomodulators, including costimulatory proteins (CD80 and CD86) involved in T-cell activation (3q21), IL-3, 4, 5, 11, 4 4 and GM-CSF (5q31-33) and beta subunit of the high affinity IgE receptors (11q13) (8) .
Finally, a genetic linkage was shown to contribute to immunologic abnormalities of AD pathogenesis (22) .
Immunologic background
Skin lesions in AD result from disturbed cellular immunity, including epidermal Langerhans cells (LCs) with IgE receptors of high and low affinity and humoral factors (increased production of IgE and collaboration with Th subsets and LCs, with resultant high production of related cytokines). There are activated Th1 cells with increased production of IFNγ in acute AD skin lesions binding to keratinocytes and, consequently, inflammatory skin changes in the disease (22) . A relative imbalance between Th1 and Th2 subsets of CD4+ T cells producing cytokines are indicative of prominent immune disorders in AD (22) . AD is product of an interaction between various susceptibility genes, host and environmental factors, infectious agents, defects in skin barrier function and immunological responses (27) . Activation of T lymphocytes, DCs, macrophages, keratinocytes, mast cells and eosinophiles are characteristic of AD skin inflammatory responses (10).
Histopathology
Clinically unaffected skin in AD is still not normal. It has a greater irritant skin response than healthy skin with microscopically sparse perivascular T-cell infiltrate, eosinophiles and macrophages (26) . There is marked infiltration of CD4+ activated memory T cell, of LCs (to a lesser extent), of IDECs, and of macrophages in lesional acute AD skin lesions. In chronic AD skin lesions is a chronic inflammation with increased collagen deposition in the dermis, and macrophages dominate in the dermal mononuclear cell infiltrate with eosinophils and smaller numbers of T cells (10, 26) .
IgE and IgE receptors
Serum IgE levels are elevated in about 80% of adult AD patients, who also show sensitization against air-borne and food allergens and/or concomitant allergic respiratory allergy (10, 28) . The subtype of AD with normal serum IgE levels has a late onset (>20 years 7 of age) and a lack of these sensitizations. Some of these patients, however, have IgE sensitization against microbial antigens (Staphylococcus aureus enterotoxins and Candida albicans or Malassezia sympodialis) with low IgE serum levels and without any detectable sensitizations. These cases develop into the extrinsic variant of AD with increasing IgE serum levels and sensitizations against air-borne and food allergens later in life.
Expression of high-affinity IgE receptor (FcεRI) can be found in the epidermal skin lesion of patients with AD because of higher IgE-binding capacity of the DCs in their skin and blood (10) .
Skin barrier disfunction
AD is characterized by dry skin and increased transepidermal water loss even in non-lesional skin, and fewer ceramides in the cornified envelope of lesional and non-lesional skin are found AD patients (10, 29) . Changes in the stratum corneum pH in AD skin may impair lipid metabolism in the skin. Such alterations allow penetration and susceptibility of irritants and allergens, triggering the inflammatory response, cutaneous hyper-reactivity, inflammation and skin damage characteristic of AD (10) . Filaggrin deficiency leads to mild or severe ichthyosis vulgaris and impaired keratinocytes differentiation and barrier formation allow increased transpidermal water loss, and entry of allergens, antigens, and chemicals from the environment in AD (30) .
Diagnosis
Well-defined diagnostic criteria are important in the diagnosis of AD and diagnostic criteria developed by Hanifin and Rajka (11) 
Diagnostic tests
The investigation of exacerbating factors in AD involves a patient history, specific skin and blood tests, and challenge tests, depending on the degree of the disease severity and on the suspected factors involved. The APT was introduced to assess sensitization to inhalant allergens in AEDS patients. Fuiano and Incorvaia (31) The APT is primarily a tool for investigating the mechanisms of eczema in the skin. It can, however, also reveal sensitization in patients with AD and might identify a subgroup of AD patients (10).
Sensitization to inhalant allergens (e.g., dust, mites, animal dander and pollen) can be detected by SPTs (if the skin is free from eczema) or by measuring specific IgE antibodies.
Contact sensitization to topical medications frequently occurs in AD patients, especially in adults. The possibility of contact allergy needs to be ruled out by patch testing (10, 33 ). There is severe dryness of the skin in AD because of an increased transepidermal water loss caused by a dysfunction of the skin barrier (10) . The regular use of emollients is important for addressing this problem and, together with skin hydration, it represents the mainstay of the general management of AD. Emollients should be applied continuously, even if no actual inflammatory skin lesions are apparent. Emollients containing polidocanol are effective in reducing pruritic symptoms. Urea is used for intensive hydration of the skin, while salicyl acid can be added to an emollient for the treatment of chronic hyperkeratotic lesions.
Topical corticosteroids (TCs)
Topical corticosteroids have been for several decades the mainstay of AD therapy and other inflammatory disorders. TCs are still important in the treatment of acute flare-ups.
Different therapeutic schemes have been established for the topical administration of TCs:
10 intermittent use may be as effective as an initial therapy with a high potent steroid followed by a time-dependent dose reduction or switch to a lower potent preparation. The choice of an adequate vehicle is important to achieve the optimal therapeutic effect. Treatment with TCs contributes to a reduction of skin colonization with S. aureus and may affect a further trigger factor of AD. Only mild-to-moderately potent preparations should be used on genital, facial, or intertriginous skin areas, in short-term application, and only mild-to-moderately potent steroid preparations should be used in children. During acute flares, steroids should be used in combination with emollient skin care to avoid steroid overuse and steroid-related side effects (10) . It is important in ADS treatment with pimecrolimus and tacrolimus according guidelines and recommendation to include optimal skin care, identification of triggers, treatment of infections and avoidance of allergens (35) . FDA raised concerns about potential malignancy risk that can be observed with increased concerns for risk for Both agents proved to be effective, with a good safety profile for a treatment period of up to 2 years with pimecrolimus and up to 4 years with tacrolimus (10, 37) . Current FDA guidelines recommend that topical pimecrolimus nad tacrolimus are indicated for the shortterm or intermittent-long-term treatment of AD in patients 2 years of age or older who are unresponsive to or intolerant of other conventional therapies or in whom there therapies are inadvisable because of potential cancer risk (35) .
Topical calcineurin inhibitors

Wet-wrap therapy
A wet layer of cotton dressing in combination with antiseptics or topical steroids (TCs) has been shown to be beneficial in cases of exacerbated AD skin lesions (10, 38) .
Topical antimicrobial therapy
Topical antiseptics, such as triclosan or chlorhexidine, offer the advantage of a low sensitizing potential and low resistance rate. They can be used in emollients or a supplement in "wet-wrap dressing" therapy. The combination of a topical antimicrobial agent to a topical steroid preparation has been shown to result in greater clinical improvement over a topical steroid alone (10) . A topical antibiotic treatment might be beneficial for the treatment of mild and localized forms of this secondary infection. Topical fusidic acid has proved to be very effective against S aureus (application for periods of no longer than about 2 weeks is advisable). Other secondary infections caused by yeasts, dermatophytes, or streptococci have also been implicated as trigger factors in AD and should be treated 
Systemic corticosteroids
In cases of acute flare-up, patients may benefit from a short course of systemic therapy with corticosteroids, but long-term use in adults and any use in children should be avoided.
Cyclosporin A
Cyclosporin is immunosuppressive and anti-inflammatory drug. T-cell receptor activation causes release of intracellular calcium that in turn binds to calmodulin and activates calcineurin. Calcineurin complex then dephosphorylates the nuclear factor of activated T-cells (NFATc) which migrate into the nucleus and make complex which is a transcription factor for inflammatory cytokines (e.g. IL-2). Cyclosporin binds to cyclophilin (intracytoplasmic proteins -immunophylin) which blocks the dephosphorylation of NFAT, resulting in a decrease of T-helper cells (CD4) and cytotoxic (CD8) in the epidermis (39) . Cyclosporin A (CyA) inhibits calcineurin-dependent pathways, resulting in reduced levels of proinflammatory cytokines, such as IL-2 and IFN-g. CyA is effective in treatment for both adult and childhood AD. Because of the possible side effects, particularly renal toxicity, the use of CyA should be limited to patients 1959 that affects purine nucleotide synthesis and is effective in severe recalcitrant AD (10) . It has a number of side-effects including myelosuppression, hepatotoxicity, and susceptibility for infection. The recommended dosage of azathioprine for dermatologic indications is 1-3 mg/kg daily but it should be determined based on thiopurine methyltransferase levels (TPMT). Knowing the baseline TPMT activity is clinical useful in the majority of patients who receive azathioprine and to monitoring during the therapy (39) . Benefits may not be apparent until 2-3 months after treatment onset.
Antihistamines
The therapeutic value of antihistamines seems to reside principally in their sedative properties, and they are useful as a short-term adjuvant to topical treatment during relapses associated with severe pruritus. The second generations antihistamines, cetirizine hydrochloride, loratadine, fexofenadine hydrochloride have distinct effect because have longer half-lives. Desloratadine has proven effectiveness in controlling pruritus.
Nonsedating antihistamines seem to have only very modest value in atopic eczema.
Leukotriene antagonists
Leukotriene antagonists (montelukast and zafirlukast) are useful for the treatment of asthma and allergic rhinitis. In AD therapy is not fully elucidated. Zafirlukast is approved in AD and asthma for adolescents and adults (5) . In chronic AD montelukast achieved little 14 14 success. Montelukast administrated 5 mg daily for four weeks in clinical double-blind study of moderate to severe AD in young patients (6-16 years) showed a significant decrease in disclose severity, but in other study with severe AD and different doses (5 mg, 10 mg, 20 mg) there was partial improvement (relieve of pruritus; abatement erythema) in few patients. AD patients failed to show any benefit from leukotriene receptor antagonist therapy (5) .
Phototherapy
The following therapy options may be used for AD: broad-band UVB (280-320 nm), narrow-band UVB (311-313 nm), UVA (320-400 nm), UVA1 (340-400 nm), PUVA, and PUVA bath. Combinations of UVB and TCs and UVB with UVA as well as UVA1 medium-and high-dose therapy are useful in AD therapy (40) . In the pediatric population, UV therapy should be restricted to children above 12 years of age. 
Interferon therapy
IgE-blocking antibody
IgE-blocking antibody omalizumab (Xolair
Conclusion
In AD complex and genetically determined aethiopathophysiology there has been major progress in the last decade, but there is no complete cure for AD. Much more clinical 
Summary
We described atopic eczema/dermatitis from the aspects of immunologic background, genetics, skin barrier dysfunction, IgE receptors, and triggers of AD (including allergens, microorganisms, and autoantigens). We have also reviewed diagnostic procedures, treatment modalities with topical treatment (emollients, topical corticosteroids, topical calcineurin inhibitors, wet wrap therapy and topical antimicrobial therapy) as well as systemic management (antimicrobials, systemic corticosteroids, cyclosporine A, azathioprine, antihistamines) and phototherapy. Finally, we have discussed primary and secondary prevention and have emphasized the role of the different cell receptors and their up-and down-regulation in this setting.
